SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trading in focus as investors weigh the potential legislative impact of a bipartisan Senate bill aimed at restricting sports betting on prediction market platforms. While bulls view the proposed regulation as a competitive moat for licensed sportsbooks, the stock remains a point of contention among the community due to ongoing insider selling activity and the company's struggle to maintain positive momentum.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing extreme volatility and intense retail interest driven by its exposure to high-profile AI and tech unicorns like SpaceX, OpenAI, and Anthropic. The community is actively debating the sustainability of its massive premium over Net Asset Value, with many investors comparing it to similar funds while some traders attempt to navigate the stock's low float and limited share availability.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is experiencing intense volatility and bearish sentiment as investors react to a recent reverse stock split, which has sparked widespread frustration regarding the company's lack of transparent guidance and perceived mismanagement. The community is actively debating whether the split will genuinely improve institutional appeal or if it is merely a precursor to further dilution, with many retail holders expressing skepticism about the company's long-term viability under current leadership.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is experiencing intense selling pressure and high volatility, fueled by investor anxiety over the company's heavy AI capital expenditures, the potential impact of competing AI models like Anthropic's Claude on legacy software, and a perceived lack of clear communication from leadership. While the community is deeply divided between those viewing the steep decline as a generational buying opportunity and those fearing a prolonged downtrend, many are actively scrutinizing the stock's recent decoupling from broader market indices.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing a wave of bullish sentiment driven by the resignation of a key FDA official and the upcoming release of pivotal Phase 1/2 clinical data for its siRNA pipeline targeting DM1 and FSHD. Community members are focusing on these potential catalysts to drive a short-term reversal, while many investors maintain a long-term outlook anchored by the company's established commercial products and the transformative potential of its rare disease pipeline.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is currently facing downward pressure following a short-seller report alleging channel stuffing, with the community actively debating whether to buy the dip or exit based on the perceived quality of management's initial response. Long-term investors are pointing to the company's fundamentals and ongoing share buyback program as evidence that the allegations are a misrepresentation aimed at driving profit for short-sellers.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant attention as traders view it as a primary proxy for exposure to major private tech players, particularly SpaceX and Anthropic. The community is actively debating the fund's heavy premium relative to its net asset value, with some retail investors aggressively accumulating shares in anticipation of a potential SpaceX IPO while others caution against the risk of dilution and overvaluation.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is trending as investors react to the company's strategic shift toward a fabless semiconductor model and the unveiling of its first in-house AGI CPU chip, which targets massive revenue growth in the AI data center market. The community is actively debating the stock's long-term potential as a primary AI infrastructure play, with many bullish investors viewing the recent volatility and price corrections as an attractive entry point for a firm now diversifying beyond traditional mobile licensing.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant market volatility following a Complete Response Letter from the FDA that rejected its drug relacorilant for the treatment of hypercortisolism, citing a need for additional evidence of effectiveness. While the company's established Cushing's syndrome franchise and ongoing oncology pipeline remain points of focus, the community is actively debating whether the steep decline represents a terminal breakdown in management credibility or a tactical buying opportunity for a cash-rich, profitable company.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing heightened investor scrutiny and volatility as community sentiment grapples with aggressive capital expenditure plans, competitive pressures in the AI space, and broader geopolitical tensions impacting the tech sector. While some traders are actively shorting the stock, citing technical weakness compared to other 'Mag 7' peers, others are highlighting the company's long-term potential in AI infrastructure and cloud growth as a reason to buy the dip.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Clark Capital Management Group Inc. Invests $7.56 Million in Amphastar Pharmaceuticals, Inc. $AMPH

Clark Capital Management Group Inc. purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the third quarter, according to the company in its most recent filing with...

Algert Global LLC Acquires 268,612 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Algert Global LLC raised its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 216.1% during the third quarter, according to its most recent filing with the...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of "Hold" from Analysts

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) have been given an average recommendation of "Hold" by the eight brokerages that are covering the firm, MarketBeat reports...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month Low - Should You Sell?

Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 12-Month Low - Should You Sell...

Vanguard Group Inc. Has $70.12 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

Vanguard Group Inc. reduced its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 2.1% in the 3rd quarter, according to the company in its most recent filing with...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 1-Year Low - Should You Sell?

Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 1-Year Low - What's Next...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 12-Month Low After Analyst Downgrade

Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 1-Year Low on Analyst Downgrade...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Issues Quarterly Earnings Results

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus...

Wells Fargo & Company Has Lowered Expectations for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price

Wells Fargo & Company decreased their target price on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set an "overweight" rating for the company in a research note on Friday...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down Following Analyst Downgrade

Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down on Analyst Downgrade...

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.72	--	--	N/A
Q4 '25	$0.92	$0.73	-20.89%	MISSED
Q3 '25	$0.83	$0.93	12.68%	BEAT
Q2 '25	$0.74	$0.85	14.61%	BEAT
Q1 '25	$0.69	$0.74	7.77%	BEAT

AMPH
Amphastar Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest AMPH News

AMPHAmphastar Pharmaceuticals Inc